Factors affecting cardioversion of atrial arrhythmias with special reference to quinidine.

ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation

“…Sotalol, but not quinidine, reduced heart rate in patients with recurrent AF, and there were fewer symptoms with sotalol. 535,592,614,[617][618][619][620][621][622][623][624] In 2 European multicenter studies, the combination of quinidine plus verapamil was as effective as or superior to sotalol in preventing recurrences of paroxysmal and persistent AF. In the Suppression Of Paroxysmal Atrial Tachyarrhythmias (SOPAT) trial, 625 1033 patients (mean age 60 y, 62% male) with frequent episodes of symptomatic paroxysmal AF either received high-dose quinidine (480 mg per day) plus verapamil (240 mg per day; 263 patients), low-dose quinidine (320 mg per day) plus verapamil (160 mg per day; 255 patients), sotalol (320 mg per day; 264 patients), or placebo (251 patients).…”

2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation

“…Other investigators (614) found sotalol and quinidine equally effective for maintaining sinus rhythm after direct-current cardioversion of AF. Sotalol, but not quinidine, reduced heart rate in patients with recurrent AF, and there were fewer symptoms with sotalol (535,592,614,(617)(618)(619)(620)(621)(622)(623)(624).…”

ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation

“…Other investigators (614) found sotalol and quinidine equally effective for maintaining sinus rhythm after direct-current cardioversion of AF. Sotalol, but not quinidine, reduced heart rate in patients with recurrent AF, and there were fewer symptoms with sotalol (535,592,614,(617)(618)(619)(620)(621)(622)(623)(624).…”